Coadministration of the B2-receptor antagonist HOE 140 abolished the antihypertrophic and antihypertensive effects of ramipril in rats with aortic banding.
Does the B2-receptor antagonist HOE 140 abolish the antihypertrophic and antihypertensive effects of ramipril in rats with aortic banding?
The antihypertrophic and antihypertensive benefits of ACE inhibitors in pressure-overload hypertrophy are mediated at least in part by bradykinin via the B2 receptor.
To evaluate the role of bradykinin in the antihypertrophic effect of the angiotensin-converting enzyme (ACE) inhibitor, ramipril, we investigated the influence of HOE 140, a specific B2-receptor antagonist, on the effects of ramipril on left ventricular hypertrophy (LVH) in rats with aortic banding. Ramipril at a dose of 1 mg kg-1 day-1 for 6 weeks prevented the increase in blood pressure and development of LVH after aortic banding; plasma ACE activity was significantly inhibited. A lower dose of ramipril (10 micrograms kg-1 day-1 for 6 weeks) had no effect on the increase in blood pressure or on plasma ACE activity, but prevented LVH after aortic banding. The antihypertrophic effects of the higher and the lower dose ramipril, as well as the antihypertensive action of the higher dose of ramipril were abolished by the coadministration of HOE 140 (500 micrograms kg-1 day-1). The present data show for the first time that the beneficial effects of an ACE-inhibitor on LVH in rats with hypertension caused by aortic banding can be prevented by a specific B2-receptor antagonist.
Linz et al. (1992) studied Left ventricular hypertrophy and hypertension. Ramipril and HOE 140 vs. Ramipril alone was evaluated on Left ventricular hypertrophy and blood pressure. Coadministration of the B2-receptor antagonist HOE 140 abolished the antihypertrophic and antihypertensive effects of ramipril in rats with aortic banding.